ASST degli Spedali Civili di Brescia
ASST degli Spedali Civili di Brescia
Brescia, Italy9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | digestive system neuroendocrine neoplasm | Active, not recruiting | Phase 3 | 2026-07-28 | NCT05050942 | |
| A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 2 | 2026-06-16 | NCT04710576 | |
| Tailored Sonidegib Schedule After Complete Response in BCC | Locally Advanced Basal Cell Carcinoma | Active, not recruiting | Phase 2 | 2026-06-01 | NCT04806646 | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) | Frontotemporal Lobar Degeneration, Nutritional and Metabolic Diseases, TDP-43 proteinopathy, brain disorder, central nervous system disorder, cognitive disorder, dementia, frontotemporal dementia, metabolic disease, nervous system disorder, neurodegenerative disease, proteostasis deficiencies, psychiatric disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-01-15 | NCT05262023 | |
| Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen | Non Small Cell Lung Cancer NSCLC | Recruiting | Phase 2 | 2025-12-18 | NCT06680050 | |
| Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 3 | 2025-09-12 | NCT03127267 | |
| A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not stated | 2025-01-14 | NCT06467383 | |
| ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation | CLL Transformation | Active, not recruiting | Phase 2 | 2024-05-28 | NCT04082897 | |
| Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Recruiting | Phase 2 | 2023-05-08 | NCT05817903 |